Immunotherapy for Renal Carcinoma

  • S. A. Brosman
Part of the NATO Advanced Science Institutes Series book series (NSSA, volume 53)


Adenocarcinoma of the kidney may be uniquely suited for attempts at immunotherapy. The natural history of this neoplasm is unusual because these patients may have long periods of time between excision of the primary tumor and development of metastases. We have observed patients in whom the primary tumor existed for 15 to 20 years before treatment was initiated. Following removal of the primary tumor, metastases rapidly appeared. Temporary regression of metastases and long term stabilization of tumors has been described. These findings suggest the presence of immune response which is able to control the development of the tumor.


Metastatic Renal Cell Carcinoma Renal Carcinoma Advanced Renal Cell Carcinoma Specific Immunotherapy Autologous Tumor Cell 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    J.B. DeKernion, Y. Katsuoka and K.P. Ramming, Immunology of Human Renal Adenocarcinoma, UICC Technical Report Series 49:96, (1980).Google Scholar
  2. 2.
    L. Horn and H.L. Horn, An Immunological Approach to the Therapy of Cancer, Lancet 2:466 (1971).PubMedCrossRefGoogle Scholar
  3. 3.
    I. Hellstrom, K.E. Hellstrom and H.O. Sjogren, Serum Factors in Tumor-Free Patients Cancelling the Blocking of Cell-Mediated Tumor Immunity, Int. J. Cancer 8:185 (1971).PubMedCrossRefGoogle Scholar
  4. 4.
    J.E. Montie, R.M. Bukowski, S.D. Deodhar, J.S. Hewlett, B.H. Stewart and R.A. Straffon, Immunotherapy of Disseminated Renal Cell Carcinoma with Transfer Factor, J. Urol. 117:553 (1977).PubMedGoogle Scholar
  5. 5.
    R.M. Bukowski, C. Groppe, R. Reimer, J. Weick and J.S. Hewlett, Immunotherapy (IT) of Metastatic Renal Cell Carcinoma, Proc. Amer. Assoc. Cancer Res. of Amer. Soc. of Clin. Oncol. 20:402 (1979).Google Scholar
  6. 6.
    D.V. Schapira, C.S. McCune and E.C. Henshaw, Treatment of Advanced Renal Cell Carcinoma with Specific Immunotherapy Consisting of Autologous Tumor Cells and C. Parvum, Proc. Amer. Assoc. Cancer Res. of Amer. Soc. of Clin. Oncol. 20:348 (1979).Google Scholar
  7. 7.
    H. Tykka, K.J. Oravisto, T. Lehtonen, S. Sharna and T. Tallberg, Active Specific Immunotherapy of Advanced Renal Cell Carcinoma, Eur. Urol. 4:250 (1978).PubMedGoogle Scholar
  8. 8.
    P.A. Brower, J.B. DeKernion and K.P. Ramming, Immune Cytolysis of Human Renal Cell Carcinoma Mediated by Xenogeneic Immune Ribonucleic Acid, J. Urol. 115:243 (1976).PubMedGoogle Scholar
  9. 9.
    K.P. Ramming and J.B. DeKernion, Immune RNA Therapy for Renal Cell Carcinoma: Survival and Immunologic Monitoring, Ann. Surg. 186:459 (1979).CrossRefGoogle Scholar
  10. 10.
    S. Brosman, Non-Specific Immunotherapy in GU Cancer, Proc. Chic. Symp. Plubl., Franklin Inst. Press., Chic. (1977) p. 97.Google Scholar
  11. 11.
    A. Morales and D. Eidinger, Bacille Calmette-Guerin in the Treatment of Adenocarcinoma of the Kidney, J. Urol., 115:377 (1976).PubMedGoogle Scholar
  12. 12.
    P.H. Lange, Lymphocyte-Mediated Cytotoxicity in Patients with Renal and Transitional Cell Carcinoma Receiving BCG, Natl. Cancer Inst. Monogr. 49:343 (1978).PubMedGoogle Scholar
  13. 13.
    J.P. Minton, K. Pennline, J.F. Nowrocki et al, Immunotherapy of Human Kidney Cancer, Proc. Am. Soc. Clin. Oncol. 17:301 (1976)Google Scholar
  14. 14.
    L.J. Humphrey, D.R. Murray and O.R. Boehm, Effect of Tumor Vaccines in Immunizing Patients with Lung Cancer, Surg. Gynecol. Obstet. 132:437 (1971).PubMedGoogle Scholar
  15. 15.
    R.C. Nairn, J. Phillip, T. Ghose et al, Production of a Precipitin Against Renal Cancer, B.M.J. 1:1702 (1963).CrossRefGoogle Scholar
  16. 16.
    G.L. Bartlett and B. Zbar, Tumor-Specific Vaccine Containing Mycobacterium Bovis and Tumor Cells: Safety and Efficacy, J. Natl. Cancer Inst. 48:170 (1972).Google Scholar
  17. 17.
    M.T. Scott, Potentiation of the Tumor-Specific Immune Response by Corynebacterium Parvum, J. Natl. Cancer Inst. 55:65 (1975).PubMedGoogle Scholar
  18. 18.
    R.L. Tuttle and R.J. North, Mechanisms of Antitumor Action of Corynebacterium Parvum: The Generation of Cell-Mediated Tumor Specific Immunity, J. Reticulothelial Soc. 20:197 (1976).Google Scholar
  19. 19.
    C.S. McCune, D.V. Schapira and E.C. Henshaw, Specific Immunotherapy of Advanced Renal Carcinoma, Cancer 47:1984 (1981).Google Scholar
  20. 20.
    G.L. Brown, P.C. Peters, M.D. Prager and S. Baechtel, Specific Immunotherapy of Metastatic Human Renal Cell Carcinoma, Presented at Amer. Urol. Assoc. Annual Meeting, Boston, Mass, (1981).Google Scholar
  21. 21.
    J.A. Neidhart, S.G. Murphy, L.A. Henrick and H.A. Wise, Active Specific Immunotherapy of Stage IV Renal Carcinoma with Aggregated Tumor Antigen Adjuvant, Cancer 46:1128 (1980).PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1983

Authors and Affiliations

  • S. A. Brosman
    • 1
  1. 1.University of CaliforniaLos AngelesUSA

Personalised recommendations